Find
News Releases
| All | ||||||
|---|---|---|---|---|---|---|
 |
Ninety-Six Week Data On Tibotec Investigational NNRTI, TMC278, Presented At AIDS 2008 Aug 5, 2008 |
7.2 KB |
|
|||
|
-Phase IIb study examines efficacy and safety of once-daily TMC278 in treatment-naïve adults with HIV-1- [Mexico City, Mexico, August 5, 2008] - New phase IIb data from Tibotec Pharmaceuticals Ltd. provides additional information on the safety and efficacy of TMC278, the company's once-daily, investigational non-nucleo... |
||||||
|
Veridex Completes Acquisition of Immunicon Corporation Assets Aug 1, 2008 |
6.2 KB |
|
|||
|
RARITAN, N.J., Aug 01, 2008 /PRNewswire via COMTEX News Network/ -- Veridex, LLC announced today it has completed its previously announced acquisition of substantially all of the assets of Immunicon Corporation (OTC Bulletin Board: IMMC) and its wholly-owned subsidiaries. The assets acquired include intellectual property, product inventory and ... |
||||||
|
Johnson & Johnson (China) Investment Co., Ltd. Acquires Beijing Dabao Cosmetics Co., Ltd. Jul 30, 2008 |
8.3 KB |
|
|||
|
SHANGHAI, July 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (China) Investment Co., Ltd. today announced that it has acquired Beijing Dabao Cosmetics Co., Ltd. from Beijing Sanlu Factory and the Beijing Dabao Co. Ltd. Staff Shareholding Committee. The acquisition was completed after receipt of all necessary gover... |
||||||
|
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Rivaroxaban Jul 30, 2008 |
8.5 KB |
|
|||
|
RARITAN, N.J., Jul 30, 2008 (BUSINESS WIRE) -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for rivaroxaban, an investigational, oral, once-daily anticoagulant for the prevention of deep vein thrombosis... |
||||||
|
FDA Grants Pediatric Exclusivity for TOPAMAX® Jul 25, 2008 |
9.6 KB |
|
|||
|
Titusville, NJ (July 24, 2008) — Ortho-McNeil Neurologics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for TOPAMAX (topiramate), based on studies submitted in response to a Written Request by the FDA to investi... |
||||||
|
FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia Jul 16, 2008 |
10.2 KB |
|
|||
|
RARITAN, N.J., July 16, 2008 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee voted in favor of the efficacy and safety data for DORIBAX(TM) (doripenem for injection) for the treat... |
||||||
|
Johnson & Johnson Reports 2008 Second-Quarter Results: Jul 15, 2008 |
28.5 KB |
|
|||
|
NEW BRUNSWICK, N.J., July 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson today announced record sales of $16.5 billion for the second quarter of 2008, an increase of 8.7% as compared to the second quarter of 2007. Operational growth was 3.1% and the positive impact of currency was 5.6%. Domestic sales were up 2.1%,... |
||||||
|
Johnson & Johnson Announces Commitment To Adopt Revised PhRMA Marketing Code for Responsible Interactions With Healthcare Professionals Jul 10, 2008 |
5.9 KB |
|
|||
|
NEW BRUNSWICK, N.J., July 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson today announced the commitment by its pharmaceutical companies to adopt the revised Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals. PhRMA introduced its new Code earlier today. ... |
||||||
|
Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results Jul 8, 2008 |
5.5 KB |
|
|||
|
NEW BRUNSWICK, N.J., July 8, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will host a conference call for financial analysts at 8:30 a.m. (Eastern Time) on Tuesday, July 15, 2008, to review second-quarter results. Dominic Caruso, Vice President, Finance and Chief Financial Officer, and Louise Mehrotra, Vice President... |
||||||
|
OneTouch® PingTM Glucose Management System Cleared by FDA Jul 1, 2008 |
9.5 KB |
|
|||
|
Animas Announces Clearance of Uniquely Integrated Meter/Pump System with Remote Insulin Delivery Capabilities and Compatible Software WEST CHESTER, PA, July 1, 2008 - Animas Corporation announced today the clearance of its OneTouch® PingTM Glucose Management System by the U.S. Food and Drug Administration (FDA). O... |
||||||
|
ETHICON Receives Offer from One Equity Partners to Purchase Professional Wound Care Business Jul 1, 2008 |
9.1 KB |
|
|||
|
SOMERVILLE, N.J., July 1, 2008 /PRNewswire via COMTEX News Network/ -- ETHICON, Inc., a Johnson & Johnson company, today announced it has received an irrevocable, unconditional offer from One Equity Partners to acquire the Professional Wound Care business. ETHICON conducted a competitive bidding process to prepare for the divestiture of the Pro... |
||||||
|
Janssen Announces Launch of Authorized Generic for RISPERDAL(R) Jun 30, 2008 |
10.1 KB |
|
|||
|
TITUSVILLE, N.J., June 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced that it has launched an authorized generic version of RISPERDAL(R) (risperidone) through Patriot Pharmaceuticals, L.L.C. Patriot is a subsidiary of McNeil-PPC. Both companies are a part of ... |
||||||
|
FDA Approves EVOLENCE®, a New Generation Collagen-Based Facial Filler Jun 30, 2008 |
12.4 KB |
|
|||
|
Herzliya, Israel and Morris Plains, NJ (June 30, 2008) - The U.S. Food and Drug Administration ("FDA") today announced the approval of EVOLENCE® for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds. EVOLENCE® is a new advanced collagen-based structural dermal filler, and a first ... |
||||||
|
FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults Jun 27, 2008 |
10.6 KB |
|
|||
|
RARITAN, N.J., June 27, 2008 /PRNewswire via COMTEX News Network/ -- ADHD is the most common emotional, cognitive and behavioral disorder treated in children(1), and according to the National Institute of Mental Health (NIMH), between 30 percent and 70 percent of children with ADHD continue to exhibit symptoms in the adult years(2). ADHD is thought... |
||||||
|
Johnson & Johnson Nordic AB Acquires Amic Jun 18, 2008 |
8.7 KB |
|
|||
|
SOLLENTUNA, Sweden, Jun 18, 2008 (Canada NewsWire via COMTEX News Network) -- Gains Access to In Vitro Diagnostic Technologies in Development for Use in Point-of-Care Settings Johnson & Johnson Nordic AB, a Johnson & Johnson company, today announced the acquisition of Amic, a privately held Swedish developer of in vitro diagnostic (... |
||||||
|
FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate To Severe Plaque Psoriasis Jun 17, 2008 |
10.0 KB |
|
|||
|
HORSHAM, PA, June 17, 2008 - Centocor, Inc. announced today that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) of the U.S. Food and Drug Administration (FDA) has unanimously recommended the approval of ustekinumab, a new subcutaneous, investigational biologic therapy for the treatment of adult patients with moderate to ... |
||||||
|
Johnson & Johnson to Participate in 29th Annual Goldman Sachs Global Healthcare Conference Jun 6, 2008 |
5.5 KB |
|
|||
|
NEW BRUNSWICK, N.J., June 6, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will participate in the 29th Annual Goldman Sachs Global Healthcare Conference on Thursday, June 12 at The Ritz-Carlton, Laguna Niguel in Dana Point, California. Christine Poon, Vice Chairman, Board of Directors and Worldwide Chairman, Pharmaceutic... |
||||||
|
Johnson & Johnson Reviews Growth Strategies for Medical Devices & Diagnostics and Consumer Businesses Jun 5, 2008 |
16.4 KB |
|
|||
|
NEW BRUNSWICK, N.J., June 5, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson is reviewing its Medical Devices & Diagnostics and Consumer businesses at a meeting with the investment community today, focusing on the strengths, strategies and innovations that will keep the broadly based health care business growing in the comi... |
||||||
|
Rivaroxaban Superior to U.S.-Approved Dosing Regimen for Enoxaparin in Reducing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial May 30, 2008 |
12.8 KB |
|
|||
|
NICE, France, May 30, 2008 (BUSINESS WIRE) -- Results from a pivotal Phase III clinical trial presented today demonstrate that rivaroxaban, an oral, once-daily, investigational anticoagulant medication, was superior in preventing venous blood clots in patients who underwent total knee replacement (TKR) surgery. The head-to-head study compared rivar... |
||||||
|
Johnson & Johnson to Host Medical Devices & Diagnostics and Consumer Business Review May 29, 2008 |
5.7 KB |
|
|||
|
NEW BRUNSWICK, N.J., May 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will host an all-day review of its Medical Devices & Diagnostics businesses, as well as an update on its Consumer businesses, for the investment community beginning at 8:30 a.m. (Eastern Time) on Thursday, June 5, 2008, at the Hyatt Regency Hotel i... |
||||||
|
||||||
= add release to Briefcase